Ignite Creation Date:
2024-05-05 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00430261
Status:
COMPLETED
Last Update Posted:
2010-10-06
First Post:
2007-01-30
Brief Title:
Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma
Sponsor:
Swedish Medical Center
Organization:
Swedish Medical Center
Study Overview
Official Title:
Phase II Trial of Sunitinib in Bronchoalveolar Carcinoma or Never-Smokers With Any Lung Adenocarcinoma
Status:
COMPLETED
Status Verified Date:
2010-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label study of a new oral drug for advanced stage IIIB or IV lung cancer The cancer must be EITHER bronchoalveolar carcinoma BAC type or if the patient is a never-smoker less than 100 cigarettes lifetime the cancer can be any type of adenocarcinoma
Detailed Description:
To participate in this study patients must have disease that can be measured on a CT scan Brain metastases are OK if stable Pregnant andor nursing women may not participate This drug has been approved by the FDA for the treatment of advanced renal cell cancer and a certain type of stomachintestinal cancer Its efficacy in lung cancer in currently unknown Common side effects include fatigue nausea diarrhea skin reaction and decreased blood counts
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None